From Locked to Learning Algorithms: Regulatory Governance of Adaptive AI/ML Models in Pharmaceutical Lifecycle Management

OM KALYANI[1], PRINCI DHAMEJANI[1], JANVI BHATT[1]
[1]Department of Pharmacy, Gyanmanjari Innovative University, Bhavnagar, Gujarat, India

Abstract- *Artificial intelligence and machine learning (AI/ML) technologies are increasingly embedded across the pharmaceutical lifecycle, influencing activities ranging from early drug discovery to post-marketing pharmacovigilance. Regulatory frameworks governing pharmaceutical products and processes have historically been designed for static systems whose behavior remains unchanged following validation and approval. In contrast, adaptive AI/ML models are capable of continuous learning from new data, enabling dynamic performance improvement while simultaneously challenging established regulatory principles related to validation, reproducibility, transparency, and accountability. This paper examines the regulatory governance implications of transitioning from locked to learning algorithms within pharmaceutical lifecycle management. By synthesizing current regulatory perspectives from major jurisdictions and aligning them with principles of Good Regulatory Practice, this study identifies key governance gaps and proposes the need for lifecycle- based regulatory oversight. The analysis highlights how adaptive AI/ML systems necessitate a shift from static approval models toward continuous, risk-based governance frameworks that ensure patient safety while supporting technological innovation.*

Index Terms- Adaptive artificial intelligence, machine learning, pharmaceutical lifecycle management, regulatory governance, GxP compliance, pharmacovigilance, regulatory science

I. INTRODUCTION

The pharmaceutical sector operates within one of the most highly regulated industrial environments, where regulatory oversight is central to ensuring patient safety, product quality, and public trust. Regulatory frameworks governing pharmaceutical development, manufacturing, and post-marketing activities are founded on principles of system stability, traceability, and reproducibility. These principles assume that critical systems influencing regulatory decisions remain consistent over time unless formally modified through predefined change control mechanisms.

Recent advances in artificial intelligence and machine learning technologies are challenging these foundational regulatory assumptions. AI/ML systems are increasingly applied across the pharmaceutical lifecycle, including target identification, clinical trial optimization, manufacturing process control, supply chain management, and pharmacovigilance. Early deployments of AI within regulated environments primarily involved rule-based or statistically driven systems with fixed logic. More recently, machine learning models capable of autonomous adaptation and continuous learning have emerged, offering substantial gains in efficiency and predictive accuracy.

Adaptive AI/ML models represent a qualitative departure from traditional software systems. Unlike locked algorithms, whose parameters and outputs remain fixed after validation, adaptive systems continuously update their internal models in response to new data. While such adaptability enhances system performance and responsiveness, it introduces significant regulatory complexity. Regulators must now address how to validate systems that evolve post-deployment, how to ensure consistent performance over time, and how to assign accountability for decisions influenced by learning algorithms.

Regulatory authorities have begun to acknowledge these challenges, particularly within the context of

digital health and software as a medical device. However, the application of adaptive AI/ML governance principles to pharmaceutical lifecycle management remains insufficiently defined. Existing regulatory frameworks largely rely on static approval paradigms that are ill-suited to dynamic, data-driven systems. This disconnect risks creating regulatory uncertainty, potentially hindering innovation or compromising safety.

The objective of this paper is to critically examine the regulatory governance challenges associated with adaptive AI/ML models across the pharmaceutical lifecycle. The study explores the limitations of current regulatory approaches and argues for a transition toward lifecycle-based governance frameworks that integrate continuous monitoring, transparency, and risk management. By situating adaptive AI/ML governance within established regulatory science principles, this paper aims to contribute to the development of regulatory models capable of accommodating technological evolution while preserving regulatory rigor.

II. CONCEPTUAL DISTINCTION BETWEEN LOCKED AND ADAPTIVE AI/ML ALGORITHMS

2.1 Locked Algorithms in Regulated Pharmaceutical Systems:

Locked algorithms are defined as AI/ML systems whose parameters, decision logic, and performance characteristics remain unchanged following deployment. Any modification to such systems requires explicit intervention by developers, followed by formal validation, documentation, and regulatory assessment where applicable. This paradigm aligns closely with traditional regulatory expectations, which emphasize system determinism and reproducibility.

In pharmaceutical contexts, locked algorithms have been deployed in applications such as quality trend analysis, rule-based decision support, and predefined statistical modeling. Their predictable behavior allows regulators to evaluate system performance against predefined acceptance criteria and to verify compliance through inspections and audits. Consequently, locked algorithms are generally compatible with existing validation frameworks under Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), and pharmacovigilance regulations.

2.2 Adaptive Learning Algorithms and Continuous Model Evolution:

Adaptive AI/ML algorithms differ fundamentally from locked systems in that they are designed to modify their behavior autonomously through exposure to new data. These models may employ online learning, incremental training, or reinforcement learning techniques to refine predictions over time. In pharmaceutical applications, adaptive models may learn from real-world clinical outcomes, manufacturing process variability, or post-marketing safety data.

The defining characteristic of adaptive algorithms is their dynamic nature. System performance is not fixed at the point of validation but evolves throughout deployment. While this capability enables improved accuracy and responsiveness, it also undermines traditional regulatory assumptions of

system stability. As a result, regulators face challenges in ensuring that adaptive systems remain within acceptable performance and risk boundaries over time.

2.3 Regulatory Implications of Algorithmic Adaptivity:

The shift from locked to adaptive AI/ML systems has significant regulatory implications. Validation must transition from a one-time activity to a continuous process. Reproducibility becomes more complex when system outputs may differ over time for identical inputs. Transparency and explainability are challenged by evolving model structures, particularly in complex architectures such as deep neural networks. Furthermore, accountability for system-driven decisions becomes less clearly defined when learning occurs autonomously.

These challenges necessitate a reconceptualization of regulatory governance models. Rather than treating AI/ML systems as static products, regulators must adopt frameworks that recognize them as evolving processes requiring ongoing oversight and risk management.

III. AI/ML INTEGRATION ACROSS THE PHARMACEUTICAL LIFECYCLE

3.1 Drug Discovery and Preclinical Development

AI/ML technologies have become integral to modern drug discovery and preclinical research. Applications include target identification, virtual screening of compound libraries, predictive toxicology, and lead optimization. Adaptive models are particularly valuable in these contexts, as they can continuously refine predictions as new experimental data become available.

Although regulatory oversight during early discovery is limited, decisions informed by AI/ML outputs influence downstream development pathways. Consequently, deficiencies in data quality, model bias, or methodological transparency at this stage may have long-term regulatory and safety implications. Establishing sound data governance and documentation practices early in the lifecycle is therefore essential.

3.2 Clinical Development

In clinical development, AI/ML systems support trial design optimization, patient recruitment, stratification, and outcome prediction. Adaptive learning algorithms may dynamically adjust trial parameters based on interim data analyses, potentially improving efficiency and ethical conduct.

However, regulatory concerns arise when adaptive systems influence clinical trial conduct in real time. Regulators must ensure that algorithm-driven adaptations do not compromise trial integrity, introduce bias, or undermine informed consent. Clear documentation of algorithmic decision rules, predefined adaptation limits, and human oversight mechanisms are critical to regulatory acceptability.

3.3 Manufacturing and Quality Management

Pharmaceutical manufacturing operates under stringent GMP requirements, with a strong emphasis on process control, data integrity, and traceability. AI/ML systems are increasingly used for process monitoring, predictive maintenance, and real-time quality analytics. Adaptive models can enhance process understanding by learning from operational data and identifying patterns associated with deviations or failures.

However, continuous learning challenges traditional validation approaches that assume system constancy. Regulators must reconcile adaptive model behavior with established quality system requirements, necessitating new approaches to validation, monitoring, and change management.

3.4 Pharmacovigilance and Post-Marketing Surveillance

Adaptive AI/ML models are particularly impactful in pharmacovigilance, where they enhance signal detection, adverse event classification, and benefit–

risk evaluation. Continuous learning allows models to incorporate real-world evidence from diverse data sources, improving sensitivity to emerging safety signals.

At the same time, regulatory oversight must address concerns related to reproducibility, explainability, and auditability. Regulators require assurance that adaptive systems support transparent and scientifically justified safety decision-making processes.

Table 1. Comparison Between Locked and Adaptive AI/ML Algorithms in Pharmaceutical Regulation

| Dimension	Locked AI/ML Algorithms	Adaptive (Learning) AI/ML Algorithms
Algorithm behavior	Static; parameters remain unchanged post-validation	Dynamic; parameters evolve based on new data
Validation approach	One-time validation prior to deployment	Continuous validation and performance monitoring
Reproducibility	High reproducibility for identical inputs	Time-dependent reproducibility due to learning
Change control	Manual change with formal revalidation	Predefined learning boundaries and controlled adaptation
Regulatory alignment	Compatible with traditional regulatory frameworks	Requires lifecycle-based regulatory governance
Risk profile	Predictable risk over time	Emergent risk due to model drift and data evolution
Transparency requirements	Conventional documentation sufficient	Enhanced transparency and explainability required
Typical pharmaceutical use	Quality analytics, rule-based decision support	Pharmacovigilance, predictive manufacturing, clinical optimization

Table 2. Regulatory Challenges Associated with Adaptive AI/ML Across the Pharmaceutical Lifecycle

Lifecycle Stage	Primary AI/ML Applications	Key Regulatory Challenges
Drug discovery	Target identification, virtual screening	Data bias, model transparency, downstream impact
Clinical development	Trial design, patient stratification	Trial integrity, ethical oversight, algorithm explainability
Manufacturing	Process control, predictive maintenance	GMP validation, data integrity, change management
Pharmacovigilance	Signal detection, risk assessment	Reproducibility, auditability, accountability
Regulatory decision support	Compliance monitoring, inspections	Trust, governance, regulatory liability

IV. CORE REGULATORY CHALLENGES ASSOCIATED WITH ADAPTIVE AI/ML SYSTEMS

4.1 Validation and Performance Assurance

Traditional regulatory validation frameworks are predicated on the assumption that system behavior remains fixed following approval. Adaptive AI/ML systems violate this assumption by design. As a result, validation must be reconceptualized as an ongoing process supported by continuous performance monitoring, predefined acceptance thresholds, and documented learning behavior.

4.2 Transparency, Explainability, and Trust

Transparency is a foundational principle of pharmaceutical regulation. Adaptive AI/ML models, particularly those employing complex architectures, may lack intuitive explainability. Regulators must balance the technical complexity of these systems with the need for sufficient transparency to support regulatory review, inspection, and accountability.

4.3 Accountability and Responsibility

The use of adaptive AI/ML systems raises questions regarding responsibility for algorithm-driven decisions. Clear allocation of accountability among system developers, pharmaceutical sponsors, and regulatory authorities is essential to ensure effective governance and ethical deployment.

V. GLOBAL REGULATORY PERSPECTIVES ON ADAPTIVE AI/ML GOVERNANCE

5.1 United States Regulatory Approach

The United States has taken a progressive position in addressing regulatory challenges associated with adaptive AI/ML systems, particularly through the initiatives of the U.S. Food and Drug Administration (FDA). The FDA has recognized that traditional premarket approval frameworks are insufficient for AI/ML systems capable of post-deployment learning and has proposed a Total Product Lifecycle (TPLC) regulatory approach. This model emphasizes continuous oversight rather than static approval, aligning regulatory control with system evolution.

Central to the FDA's approach is the concept of predefined change control plans, wherein developers specify the types of algorithmic modifications that may occur post-authorization, the methodologies used for learning, and the performance metrics employed to monitor safety and effectiveness. While initially developed for Software as a Medical Device (SaMD), these principles are increasingly relevant for AI/ML applications in pharmaceutical manufacturing, clinical decision support, and pharmacovigilance.

Despite these advancements, the regulatory application of TPLC principles to broader pharmaceutical lifecycle management remains in an early stage. Challenges persist in translating device-focused guidance into pharmaceutical quality systems governed by Good Manufacturing Practice (GMP),

Good Clinical Practice (GCP), and pharmacovigilance regulations.

5.2 European Union Regulatory Landscape
The European Union has adopted a risk-based regulatory framework for artificial intelligence through the proposed Artificial Intelligence Act. This legislation classifies AI systems according to their potential impact on safety, public health, and fundamental rights. AI systems deployed in regulated healthcare and pharmaceutical environments are categorized as high-risk, subjecting them to stringent requirements related to governance, transparency, documentation, and post-market monitoring.

The EU approach emphasizes accountability, human oversight, and traceability, which align closely with pharmaceutical regulatory principles. However, the AI Act does not explicitly differentiate between locked and adaptive learning algorithms, creating interpretive challenges for pharmaceutical sponsors seeking to deploy continuously learning systems. The absence of detailed guidance on managing post-deployment learning highlights the need for supplementary regulatory instruments and harmonized implementation strategies.

5.3 Emerging Regulatory Ecosystems
Regulatory authorities in emerging markets, including India and other developing regions, are gradually integrating digital technologies into pharmaceutical oversight. While national strategies increasingly recognize the importance of AI governance, explicit regulatory frameworks for adaptive AI/ML in pharmaceutical contexts remain limited.

In these jurisdictions, regulatory governance is often constrained by resource limitations and evolving institutional capacity. This underscores the importance of international harmonization and knowledge transfer to ensure that adaptive AI/ML adoption does not exacerbate regulatory disparities or compromise global pharmaceutical safety standards.

VI. LIFECYCLE-BASED REGULATORY GOVERNANCE FRAMEWORK FOR ADAPTIVE AI/ML

6.1 Rationale for Lifecycle-Based Governance
Adaptive AI/ML systems cannot be effectively regulated through static approval models that assume post-authorization stability. Instead, governance must be embedded across the entire lifecycle of system development, deployment, and use. A lifecycle-based regulatory governance framework aligns oversight mechanisms with the dynamic characteristics of learning algorithms while preserving regulatory control.

Such a framework integrates risk assessment, performance monitoring, transparency, and accountability at each stage of system operation. It shifts regulatory focus from episodic evaluation to continuous assurance, consistent with modern regulatory science principles.

6.2 Pre-Deployment Regulatory Controls
Pre-deployment governance should include a comprehensive assessment of intended use, risk classification, and decision impact. Adaptive AI/ML systems influencing safety-critical pharmaceutical

decisions should be subject to enhanced regulatory scrutiny.

Regulators should require detailed documentation of training datasets, including data provenance, representativeness, preprocessing methods, and bias mitigation strategies. Algorithmic transparency should be addressed through clear descriptions of model architecture, learning mechanisms, and known limitations.

Critically, predefined learning boundaries must be established. These boundaries specify the scope of permissible algorithmic adaptations without triggering regulatory reapproval, thereby enabling controlled learning while maintaining regulatory predictability.

6.3 Deployment and Continuous Performance Monitoring

During deployment, adaptive AI/ML systems must operate under continuous performance monitoring frameworks. These frameworks should define key performance indicators, drift detection thresholds, and corrective action protocols. Deviations beyond acceptable limits should initiate predefined responses, including model retraining, rollback, or regulatory notification.

Auditability is a central requirement. Systems should maintain comprehensive audit trails documenting data inputs, model updates, and output changes over time. These records support regulatory inspections, root-cause analysis, and accountability for AI-driven decisions.

Regular regulatory reporting mechanisms should be established to communicate system performance, learning behavior, and identified risks. This approach supports a transition from static compliance to dynamic regulatory engagement.

6.4 Post-Market Oversight and Reassessment

Post-market oversight is essential for detecting emergent risks associated with adaptive learning. Continuous benefit–risk evaluation should be conducted using real-world evidence and performance data. Regulators should retain authority to mandate audits, impose operational restrictions, or suspend system use if unacceptable risks are identified.

Controlled retraining protocols should be implemented to manage significant model updates. These protocols must align with pharmaceutical change management principles and clearly distinguish between minor adaptive updates and major modifications requiring regulatory reassessment.

Table 3. Lifecycle-Based Regulatory Controls for Adaptive AI/ML Systems

Governance Phase	Regulatory Objective	Key Controls
Pre-deployment	Risk identification and containment	Intended use definition, data governance, learning boundaries
Deployment	Performance assurance	Continuous monitoring, drift detection, audit trails
Post-market	Long-term safety and compliance	Benefit–risk reassessment, audits, controlled retraining
Regulatory interaction	Oversight and transparency	Periodic reporting, inspection readiness, regulatory triggers

## VII. DOMAIN-SPECIFIC REGULATORY IMPLICATIONS

7.1 Adaptive AI/ML in Pharmaceutical Manufacturing

In GMP-regulated manufacturing environments, adaptive AI/ML systems support predictive maintenance, process optimization, and real-time quality monitoring. While these applications offer substantial efficiency gains, continuous learning challenges traditional validation models based on fixed system behavior.

Lifecycle-based governance reconciles adaptive learning with GMP principles by reframing validation as continuous verification. Performance monitoring, data integrity controls, and human oversight ensure that adaptive systems enhance, rather than undermine, manufacturing compliance.

7.2 Adaptive AI/ML in Pharmacovigilance

Pharmacovigilance represents a high-impact domain for adaptive AI/ML deployment. Learning algorithms improve signal detection sensitivity by continuously integrating real-world data from diverse sources. However, regulators must ensure that evolving algorithms do not compromise transparency or reproducibility in safety assessments.

Governance frameworks should require explainable signal prioritization criteria, documented learning behavior, and human review of safety decisions. These measures preserve regulatory confidence while enabling innovation in post-marketing surveillance.

VIII. DISCUSSION

Table 4. Mapping of Adaptive AI/ML Governance to Existing Pharmaceutical Regulatory Principles

Regulatory Principle	Traditional Interpretation	Adaptation for Adaptive AI/ML
Validation	Static confirmation of fitness	Continuous verification and monitoring
Change management	Discrete, manual updates	Predefined algorithmic adaptation
Risk management	Pre-approval risk assessment	Ongoing benefit–risk evaluation
Data integrity	Fixed datasets	Dynamic data streams with auditability
Accountability	Human decision-makers	Shared accountability with human oversight

The governance of adaptive AI/ML systems represents a fundamental regulatory challenge that extends beyond technical validation. It requires a systemic transformation in regulatory philosophy, institutional capacity, and stakeholder collaboration. Static approval paradigms are increasingly incompatible with technologies designed for continuous learning.

Lifecycle-based governance offers a viable regulatory pathway by embedding oversight mechanisms throughout system operation. However, successful implementation depends on regulatory expertise in data science, algorithmic risk assessment, and digital inspection methodologies. Capacity building within regulatory agencies is therefore a critical priority.

Global harmonization remains an unresolved challenge. Divergent regulatory approaches risk fragmenting oversight and complicating multinational pharmaceutical operations. International collaboration through established regulatory harmonization bodies is essential to develop shared principles for adaptive AI/ML governance.

IX. LIMITATIONS

This study is conceptual and policy-oriented, lacking empirical validation through regulatory pilot programs or case studies. The proposed framework requires practical evaluation in real-world regulatory settings to assess feasibility and effectiveness.

Additionally, rapid technological advancements may necessitate continuous refinement of governance approaches. Future research should focus on empirical evidence derived from regulatory implementations of adaptive AI/ML systems.

X. FUTURE REGULATORY ROADMAP

Over the next decade, regulatory governance of adaptive AI/ML systems is expected to evolve toward greater reliance on real-world evidence, regulatory sandboxes, and automated monitoring tools. By 2030, lifecycle-based governance models are likely to become standard practice in AI- enabled pharmaceutical regulation.

Regulators may increasingly function as continuous partners in system oversight rather than episodic approvers. This evolution has the potential to enhance both regulatory effectiveness and innovation capacity.

XI. CONCLUSION

Adaptive AI/ML models offer transformative potential across the pharmaceutical lifecycle but fundamentally challenge regulatory frameworks designed for static systems. Effective governance requires a transition toward lifecycle-based regulatory models grounded in continuous monitoring, transparency, and risk management.

By aligning regulatory oversight with the dynamic nature of learning algorithms, regulators can safeguard patient safety while enabling responsible innovation. The framework proposed in this study contributes to regulatory science by providing a structured approach to governing adaptive AI/ML systems in pharmaceutical lifecycle management.

REFERENCES

[1] U.S. Food and Drug Administration. (2021). Artificial Intelligence and Machine Learning in Software as a Medical Device (Discussion Paper and Proposed Regulatory Framework). U.S. FDA. https://www.fda.gov/media/151293/download

[2] U.S. Food and Drug Administration. (2023). Proposed Regulatory Framework for Adaptive Machine Learning in Medical Devices.

[3] https://www.fda.gov/media/XXXXXX/download

[4] European Commission. (2021). Proposal for a Regulation Laying Down Harmonised Rules on Artificial Intelligence (Artificial Intelligence Act). https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52021PC0206

[5] World Health Organization. (2021). Ethics and Governance of Artificial Intelligence for Health: WHO Guidance. WHO Press.

https://www.who.int/publications/i/item/97892 40029200

[6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2005). ICH Q9: Quality Risk Management. ICH Secretariat. https://www.ich.org/page/quality-guidelines

[7] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2008). ICH Q10: Pharmaceutical Quality System. ICH Secretariat. https://www.ich.org/page/quality-guidelines

[8] European Medicines Agency. (2020). Regulatory Science Strategy to 2025. European Medicines Agency. https://www.ema.europa.eu/en/documents/other/regulatory-science-strategy-2025_en.pdf

[9] Price, W. N., & Cohen, I. G. (2019). Privacy in the Age of Medical Big Data. Nature Medicine, 25(1), 37–43.

[10] https://doi.org/10.1038/s41591-018-0272-7

[11] Topol, E. J. (2019). High-Performance Medicine: The Convergence of Human and Artificial Intelligence. Nature Medicine, 25(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7

[12] Reddy, S., Fox, J., & Purohit, M. P. (2019). Artificial Intelligence-Enabled Healthcare Delivery. Journal of the Royal Society of Medicine, 112(1), 22–28. https://doi.org/10.1177/0141076819828610

[13] Holzinger, A., Biemann, C., Pattichis, C. S., & Kell, D. B. (2017). What do We Need to Build Explainable AI Systems for the Medical Domain? Reviews in the Biomedical Engineering, 9, 1–33. https://doi.org/10.1515/revce-2017-0014

[14] Benjamens, S., Dhunnoo, P., & Mesko, B. (2020). The State of Artificial Intelligence–Based FDA-Approved Medical Devices and Algorithms: An Online Database. NPJ Digital Medicine, 3, Article 118. https://doi.org/10.1038/s41746-020-00324-9

[15] Morley, J., Machado, C. C. V., Burr, C., Cowls, J., Joshi, I., Taddeo, M., & Floridi, L. (2021). The Ethics of AI in Health Care: A Mapping Review. Social Science & Medicine, 270, 113558. https://doi.org/10.1016/j.socscimed.2020.113558

[16] Ghassemi, M., Naumann, T., Schulam, P., Beam, A. L., Chen, I. Y., & Ranganath, R. (2021). A Review of Challenges and Opportunities in Machine Learning for Health. AMIA Joint Summits on Translational Science Proceedings, 2021, 191–200.

[17] Silver, D., Schrittwieser, J., Simonyan, K., et al. (2017). Mastering the Game of Go without Human Knowledge. Nature, 550, 354–359. https://doi.org/10.1038/nature24270

[18] National Institute for Standards and Technology. (2020). Draft NIST AI Risk Management Framework. NIST.

[19] https://www.nist.gov/itl/ai-risk-management-framework

[20] Strubell, E., Ganesh, A., & McCallum, A. (2019). Energy and Policy Considerations for Deep Learning in NLP. Proceedings of ACL 2019, 3645–3650. https://doi.org/10.18653/v1/P19-1355

[21] Wiens, J., Saria, S., Sendak, M., et al. (2019). Do No Harm: A Roadmap for Responsible Machine Learning for Health Care. Nature Medicine, 25(9), 1337–1340. https://doi.org/10.1038/s41591-019-0548-6

[22] U.S. Government Accountability Office (GAO). (2020). Artificial Intelligence: Status of Agencies' Use, Challenges, and Governance Approaches. GAO Publications. https://www.gao.gov/products/gao-20-519

[23] European Commission High-Level Expert Group on AI. (2019). Ethics Guidelines for Trustworthy AI. https://ec.europa.eu/digital-single-market/en/news/ethics-guidelines-trustworthy-ai

[24] Krittanawong, C., Johnson, K. W., & Wang, Z. (2019). Deep Learning for Cardiovascular Medicine: A Practical Primer. European Heart Journal, 40(18), 1332–1340. https://doi.org/10.1093/eurheartj/ehy340

[25] Davenport, T. H., & Kalakota, R. (2019). The Potential for AI in Healthcare. Future Healthcare Journal, 6(2), 94–98. https://doi.org/10.7861/futurehosp.6-2-94

[26] Lee, C. S., Bubeck, S., & Petro, J. (2021). Human-Centered AI in Medicine: The Case of Radiology. Journal of the American Medical Association, 326(19), 1904–1905. https://doi.org/10.1001/jama.2021.17643

[27] Obermeyer, Z., & Emanuel, E. J. (2016). Predicting the Future — Big Data, Machine Learning, and Clinical Medicine. New England Journal of Medicine, 375, 1216–1219. https://doi.org/10.1056/NEJMp1606181

[28] Becquemont, L. (2022). Regulatory Challenges for AI in Drug Development and Life Cycle Management. Regulatory Rapporteur, 19(9), 12–20.

[29] Lee, J., Yoon, W., & Kim, Y. (2022). Risk Management Techniques for AI-Based Decision Systems. Journal of Regulatory Science, 13(4), 56–72.

[30] Brunetti, M., Fadda, A., & Conte, G. (2023). Implementation of Adaptive Algorithms in Pharmaceutical Manufacturing: A Review. Journal of Pharmaceutical Innovation, 18(2), 210-225.

[31] Chen, J., Zhou, Y., & Chen, J. (2023). AI/ML Algorithm Transparency and Accountability in Clinical Practice. Journal of Healthcare Informatics Research, 7(1), 45-67.

[32] Liang, H., Tsui, B., & Ni, H. (2020). Evaluation and Accuracy Assessment of AI-Based Medical Tools. PLoS ONE, 15(5), e0233350. https://doi.org/10.1371/journal.pone.0233350

[33] Vayena, E., Blasimme, A., & Cohen, I. G. (2018). Machine Learning in Medicine: Addressing Ethical Challenges. PLoS Medicine, 15(11), e1002689. https://doi.org/10.1371/journal.pmed.1002689